Numeta G 13 % E

Valine, the active ingredient in Numeta G 13% E, is a nutrition supplement presented as a 13% solution for oral use. It supports metabolic and protein needs in patients requiring specialized nutritional support, particularly in critical care settings. GNH USA supplies Numeta G 13% E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Numeta G 13% E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Numeta G 13% E is used in clinical nutrition to address protein and amino‑acid requirements in several metabolic conditions.

- Critical illness: helps provide the essential amino acids needed for tissue repair and immune function. - Post‑operative recovery: supports protein synthesis for wound healing. - Severe malnutrition: supplies a balanced amino‑acid profile to restore nitrogen balance. - Chronic kidney disease: offers a controlled amino‑acid composition that is easier for the kidneys to process. - Liver disease of cirrhosis or failure : provides a form of protein that is metabolised with reduced hepatic stress.

Numeta G 13% E may cause adverse reactions that are generally mild and related to its composition.

Common Side Effects: - Nausea: mild stomach upset reported by some patients. - Diarrhea: loose stools occurring after oral administration. - Abdominal discomfort: cramping or bloating sensations. - Metallic taste: transient alteration in taste perception. - Hypernatremia: slight increase in serum sodium in susceptible individuals.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling indicating hypersensitivity. - Anaphylaxis: severe, potentially life‑threatening systemic reaction. - Metabolic acidosis: rare disturbance in acid‑base balance. - Hyperosmolarity: elevated serum osmolarity in patients with impaired renal function. - Seizure risk: extremely rare neurological event linked to electrolyte shifts.

When using Numeta G 13% E, clinicians should consider several safety measures.

- Assess renal function: evaluate kidney performance before initiating therapy. - Monitor electrolytes: regularly check serum sodium, potassium and osmolarity. - Evaluate nutritional status: ensure the product matches the patient’s protein needs. - Adjust for liver disease: modify dosage in hepatic impairment. - Use caution in pregnancy: limited data, weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Numeta G 13% E can interact with other medications and nutritional products.

Major Interactions (Avoid): - High‑protein supplements: concurrent use may cause excess nitrogen load. - Sodium‑containing IV fluids: combined sodium load can increase risk of hypernatremia.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify electrolyte disturbances. - ACE‑ inhibitors: potential for altered potassium levels. - Antiepileptic drugs: amino‑acid composition may affect drug metabolism. - Oral anticoagulants: changes in plasma protein binding could modify effect. - Proton‑pump inhibitors: may affect gastric pH and absorption of amino acids.